The life sciences industry is undergoing rapid digital transformation, fueled by the need for greater agility, regulatory compliance, and patient-centric operations. Enterprise platforms such as SAP, Oracle, and Salesforce have evolved from back-end systems of record to strategic innovation enablers, powering R&D, strengthening supply chains, and enhancing commercial effectiveness. However, challenges remain, as many organizations still operate fragmented legacy systems, struggle with complex migrations, and navigate the trade-offs between global standardization and local compliance. To address these needs, providers are investing in industry-specific accelerators, compliance-ready architectures, and intelligent automation capabilities. They are strengthening their expertise across SAP, Oracle, and Salesforce platforms, while also expanding AI/ML offerings to drive more proactive, insights-led operations. In this report, we assess 20 life sciences enterprise platform providers and position them on Everest Group’s PEAK Matrix®, a composite index of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performances against each other. Scope Industry: life sciences Geography: global Services: life sciences enterprise platform services Contents In this report, we examine: The provider landscape for life sciences enterprise platform services Life sciences enterprise platform providers on several capabilities and market success-related dimensions

The life sciences R&D engine is rapidly digitizing, and clinical development software now sits at its center. This report sizes the global clinical trials technology market at nearly US$6.5 billion for 2025 (8-10% CAGR) and dissects its four core segments – Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Decentralized Clinical Trial (DCT) platforms, and clinical data and analytics suites. This study maps demand surges in oncology, rare disease, neurology, and obesity trials and examines the contrasting pressures of build-versus-buy debates and heightened data privacy scrutiny. Beyond market numbers, the report spotlights whitespaces such as end-to-end interoperability, real-time visualization, and true low/no-code configurability, analyzes segment-specific product trends (AI-driven EDC validation, next-generation CTMS forecasting, patient-centric DCT designs, and unified analytics hubs), and details the investment priorities sponsors and CROs are setting for 2025. A forward-looking section explores generative AI and agentic AI use cases, from autonomous protocol design to real-time safety monitoring, and outlines adoption stages and success prerequisites. These insights equip stakeholders to refine technology roadmaps, close capability gaps, and accelerate drug-development timelines. Scope Industry: life sciences Geography: global Contents In this report, we examine: 2023-25 clinical technology market size, growth, and segment mix Therapeutic area demand and shifting R&D spend Growth drivers and inhibitors Persistent gaps and sponsor-sourcing criteria Product-innovation themes across EDC, CTMS, DCT, and analytics High-potential generative AI and agentic AI applications and adoption stages 2025 investment priorities for sponsors, CROs, and technology providers

Clinical Trial Management Systems (CTMS) are vital to modern clinical research, offering essential tools to manage and track all operational aspects of the trial process. Clinical trials’ increasing complexity, the growing data volume, and the need for enhanced collaboration have transformed CTMS platforms from basic on-premise, siloed data management systems to cloud-based, integrated systems. Initially focused on addressing manual, paper-based limitations, early CTMS lacked integration capabilities. Over time, technology advances, regulatory demands, and growing trial complexity led to the emergence of modern CTMS platforms that offer enhanced features such as integration with electronic health records, remote monitoring, and real-time actionable insights. CTMS platform providers continue to invest in AI/ML, automation, and advanced analytics to enable more efficient clinical trials. By providing real-time insights, automating routine processes, and allowing better data management, modern CTMS platforms ensure trial operations are streamlined and more effective, leading to more informed decision-making and faster trial execution. In this report, we assess 13 CTMS providers’ capabilities. The providers are mapped on the Everest Group PEAK Matrix®, a composite index of a range of distinct metrics related to a provider’s capability and market impact. Scope Industry: life sciences Geography: global Contents In this report, we assess: The CTMS product provider landscape CTMS product providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

In the dynamic life sciences clinical development field, patient engagement has emerged a vital innovation and success driver. As clinical research evolves, integrating patient perspectives and active participation has become a transformative force, significantly enhancing clinical trials’ quality and relevance. Effective patient engagement throughout the clinical trial process, from study design and recruitment to data collection and result dissemination, ensures that trials are more patient-centric, efficient, and likely to yield meaningful insights. Patient engagement in clinical development is not merely a regulatory requirement but a strategic imperative. Patients who are engaged are more likely to participate in clinical trials and remain committed throughout the study, thereby reducing dropout rates and accelerating the research timeline. In this report, we assess start-ups that provide clinical trial patient engagement solutions, offering insights into capabilities, market impact, and the evolving landscape. Furthermore, from creating patient advisory boards to using patient-reported outcomes, we will explore practical strategies to incorporate patient engagement into clinical development. We will also examine case studies and best practices that illustrate patient-centric approaches’ tangible benefits. Scope Industry: life sciences Geography: global Contents In this report, we Examine the drivers and barriers to patient engagement solution adoption in clinical trials Introduce a framework to evaluate high-potential start-ups in the patient engagement market Highlight the trailblazers in patient engagement, including their assessment, leaderboard, and profiles Membership(s) Clinical Development Technology Sourcing and Vendor Management

Drug development is a complex, time-consuming, and expensive process. The average cost to develop a new drug has increased from US$1.3 million in 2013 to US$2.3 billion in 2022. This cost increase poses a significant challenge for life sciences enterprises, especially considering that the Food and Drug Administration approves only about 12% of drugs entering clinical trials. The current scenario is not ideal, and life sciences enterprises must prioritize making their drug development processes sustainable in the long term. As the industry faces rising development costs and shrinking research and development returns, gen AI-led digital transformation has become a top priority. Gen AI is revolutionizing the life sciences value chain with use cases in drug development, clinical development, manufacturing, and sales and marketing. In this viewpoint, we share insights and our perspective on gen AI’s impact on the life sciences industry. Scope Industry: pharmaceutical Geography: global Contents In this report, we: Examine current gen Al adoption in the life sciences industry Analyze key gen AI use cases and their potential benefits Evaluate gen Al’s impact on enterprises and technology and service providers Assess best practices and challenges for successful gen AI implementation Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Gen AI can create diverse content and data formats, revolutionizing the AI landscape and transforming businesses. The pharmaceutical industry can use gen AI to sift through vast clinical data volumes, enabling trial protocols’ drafting and improving clinical trial success rates. In this viewpoint, we present Everest Group’s findings from a survey of 50 pharmaceutical enterprises to evaluate their gen AI expectations, its adoption patterns, and insights into the technology’s role in clinical development. The report offers detailed insights into gen AI’s applications, potential impact, adoption challenges, and best practices to achieve a strategic advantage in the dynamic technology landscape. Pharmaceutical companies can use this report to gain valuable peer perspectives on gen AI, identify essential functionalities when choosing tools/platforms, and understand gen AI’s role in achieving business objectives. Scope Industry: pharmaceutical Geography: global Contents In this report, we: Assess pharmaceutical enterprises’ gen AI objectives Evaluate investment strategies and procurement initiatives to implement gen AI solutions Identify gen AI’s adoption challenges Recommend an enterprise framework to adopt and scale gen AI initiatives Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by leveraging digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the aftermath of the pandemic, a hybrid model is emerging that seamlessly integrates technology with traditional site workflows, ushering in a new era of clinical trials that harnesses the strengths of both approaches. In a financially constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They prioritize delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. This compendium provides detailed and fact-based snapshots of 22 DCT providers. Each profile offers a comprehensive picture of the provider’s offerings, technology solutions, key clients, recent developments, and investments. Scope Industry: Life sciences Geography: global Contents This report features 22 DCT platform provider profiles and includes: Company overview: the company’s mission, client base, and revenue split across buyer segment and geographies Case studies demonstrating DCT capabilities Solutions/Products enabling DCT capabilities Recent product developments, partnerships, and investment areas Membership(s) Clinical Development Technology Outsourcing Excellence

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by harnessing digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the post-pandemic climate, a hybrid model is emerging that seamlessly integrates technology advances with traditional site workflows, creating a new era of clinical trials that harnesses the strengths of both. In a funding-constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They are focusing on delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. In this report, we assess the capabilities of 22 platform providers specific to the decentralized clinical trial landscape. These platform providers are mapped on the Everest Group PEAK Matrix® , a composite index of a range of distinct metrics related to a provider’s capability and market impact. Scope Industry: Life sciences clinical development technology Geography: global Contents In this report, we: Examine the provider landscape for DCTs Assess DCT platform providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

The pandemic accelerated the need to extract value from data due to the substantial increase in data generation from various clinical sources, characterized by high veracity, variety, and volume. As a result, the adoption of clinical Data and Analytics (D&A) platforms in clinical development has notably surged. This prompted a considerable interest in assessing their impact on clinical trials, patient care, treatment outcomes, and health system efficiency. The integration of complex clinical data sources including Electronic Health Records (EHR), Electronic Medical Records (EMR), laboratory data, Clinical Trial Management Systems (CTMS), connected devices, and Real-world Data (RWD), presents a significant challenge that the industry currently faces. Clinical D&A platforms provide significant benefits in the realm of clinical development. These platforms enhance data management by facilitating centralized and standardized data collection from various sources, resulting in improved data quality and integrity. Real-time monitoring capabilities enable stakeholders to track trial progress, identify potential issues, and make informed decisions. Advanced analytics tools help uncover patterns, trends, and correlations within the data, providing valuable insights for optimizing trial protocols and treatment strategies. In this compendium, we provide comprehensive and fact-based snapshots of 14 platform providers specific to clinical D&A. In addition, each provider is positioned on Everest Group’s PEAK Matrix® for comparison. The compendium will enable providers to benchmark their capabilities against their competitors, while buyers of clinical D&A platforms will be able to assess the providers based on their desired set of capabilities. Scope Industry: life sciences Geography: global Contents In this report, we evaluate clinical D&A platform providers on their: Market adoption and capabilities Case studies and recent developments Strengths and limitations Sourcing considerations Membership(s) Clinical Development Technology Sourcing and Vendor Management